- Homepage - GRAIL
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
- Careers - GRAIL
Everything we do is guided by our mission to detect cancer early, when it can be cured We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
- GRAIL Reports First Quarter 2025 Financial Results
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
- GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
- Multi-cancer early detection - GRAIL
The Galleri test was developed, and its performance characteristics were determined by GRAIL The Galleri test has not been cleared or approved by the U S Food and Drug Administration
- Investor Relations - GRAIL, Inc.
GRAIL, Inc Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts
- GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
- GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results . . .
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
|